Brian Grindel, Ph.D.
Department of Cancer Systems Imaging, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Instructor, Cancer Systems Imaging, Diagnostic Imaging, UT MD Anderson, Houston, Texas
Education & Training
Degree-Granting Education
| 2015 | Rice University, Houston, Texas, US, Biochemistry and Cell Biology, Ph.D |
| 2008 | University of Delaware, Newark, Delaware, US, Biological Sciences, BS |
Postgraduate Training
| 2017-2022 | Research Fellowship, UT MD Anderson |
| 2017-2017 | Research Fellowship, Dept. of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas |
| 2016-2017 | Research Fellowship, BioScience Research Collaborative, Rice University, Houston, Texas |
| 2009-2015 | Research Assistant, Rice University, Houston, Texas |
Experience & Service
Other Professional Positions
Research Scientist, UT MD Anderson, 2022 - 2023
Honors & Awards
| 2021 | Best short presentation, University of Texas MD Anderson Cancer Center |
| 2020 | Postdoctoral Travel Award, The University of Texas MD Anderson Cancer System |
| 2018 | Best poster presentation, NCI Alliance for Nanotechnology in Cancer |
| 2017 | Translational Cancer Nanotechnology Training Fellowship, NIH |
| 2015 | George J. Schroepfer Award, Rice University |
| 2014 | Best Presentation, Rice University |
| 2013 | Travel Grant Award, Rice University |
| 2013 | First Place, Rice University |
| 2010 | Nomination, Rice University |
| 2009 | Chemistry/Biology Interface fellowship, University of Delaware |
| 2008 | Biological Sciences Academic Achievement Award, University of Delaware |
| 2008 | Richard M. Johnson Jr. Memorial Award, University of Delaware |
| 2007 | Goldwater Award, Goldwater Foundation |
| 2005 - 2006 | Research Stipend Recipient, Howard Hughes Medical Institute |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. CycloSal Prodrugs for the Treatment of ENO1-deleted and ENO1-heterozygous Tumors. Poster. Metabolism in Cancer Symposia.
Selected Publications
Peer-Reviewed Articles
- Jeevarathinam AS, Kawelah MR, Han S, Grindel BJ, Millward SW, Johnston KP, Sokolov KV. Directional conjugation of monoclonal antibodies to nanoparticles using metal-free click chemistry. Nat Protoc, 2025. e-Pub 2025. PMID: 41258016.
- Ong JN, Grindel BJ, Rankin SA, Naylon SH, Srinivasamani A, Trusz GJ, Liang X, Uddin MN, Fuller L, Curran M, Roche SP, Takahashi TT, Roberts RW, Millward SW. Using extension-based mRNA display to design antibody-like proteinogenic peptides for human PD-L1. Protein Sci 34(9):e70268, 2025. e-Pub 2025. PMID: 40852896.
- Engel BJ, Paolillo V, Uddin MN, Gonzales KA, McGinnis KM, Sutton MN, Patnana M, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568603.
- Grindel BJ, Engel BJ, Ong JN, Srinivasamani A, Liang X, Zacharias NM, Bast RC, Curran MA, Takahashi TT, Roberts RW, Millward SW. Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol 17(6):1543-1555, 2022. e-Pub 2022. PMID: 35611948.
- Tellman TV, Cruz LA, Grindel BJ, Farach-Carson MC. Cleavage of the Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex by Matrix Metalloproteinase 7/Matrilysin Triggers Prostate Cancer Cell Dyscohesion and Migration. Int J Mol Sci 22(6), 2021. e-Pub 2021. PMID: 33809984.
- Gray JP, Uddin MN, Chaudhari R, Sutton MN, Yang H, Rask P, Locke H, Engel BJ, Batistatou N, Wang J, Grindel BJ, Bhattacharya P, Gammon ST, Zhang S, Piwnica-Worms D, Kritzer JA, Lu Z, Bast RC, Millward SW. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
- Grindel BJ, Engel BJ, Hall CG, Kelderhouse LE, Lucci A, Zacharias NM, Takahashi TT, Millward SW. Mammalian Expression and In Situ Biotinylation of Extracellular Protein Targets for Directed Evolution. ACS Omega 5(39):25440-25455, 2020. e-Pub 2020. PMID: 33043224.
- Kamalinia G, Engel BJ, Srinivasamani A, Grindel BJ, Ong JN, Curran MA, Takahashi TT, Millward SW, Roberts RW. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1). ACS Chem Biol 15(6):1630-1641, 2020. e-Pub 2020. PMID: 32352272.
- Engel BJ, Grindel BJ, Gray JP, Millward SW. Purification of poly-dA oligonucleotides and mRNA-protein fusions with dT25-OAS resin. Bioorg Med Chem Lett 30(4):126934, 2020. e-Pub 2020. PMID: 31919017.
- Martinez JR, Grindel BJ, Hubka KM, Dodge GR, Farach-Carson MC. Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome. J Cell Biochem 120(2):2138-2150, 2019. e-Pub 2019. PMID: 30203597.
- Grindel BJ, Martinez JR, Tellman TV, Harrington DA, Zafar H, Nakhleh L, Chung LW, Farach-Carson MC. Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells. Sci Rep 8(1):7262, 2018. e-Pub 2018. PMID: 29740048.
Review Articles
- Kamalinia G, Grindel BJ, Takahashi TT, Millward SW, Roberts RW. Directing evolution of novel ligands by mRNA display. Chem Soc Rev 50(16):9055-9103, 2021. e-Pub 2021. PMID: 34165126.
Patient Reviews
CV information above last modified August 31, 2026